Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00002759
Phase
PHASE1
Status
Completed

Conditions

  • Drug/Agent Toxicity by Tissue/Organ
  • Lymphoma
  • Neutropenia
  • Small Intestine Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in treating patients who have solid tumors or lymphoma that is refractory to standard therapy. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Cyclosporine and phenobarbital may enhance the effectiveness of irinotecan.

Key Dates

Start date
Jun 30, 1996
Status verified
May 2006
Primary completion
Apr 30, 2002

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    See detailed description.

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Cancer Research CenterChicagoIllinois60637-1470-

Find similar trials in Chicago, IL

By research site
University of Chicago Cancer Research Center· Chicago, IL

Related Studies